MSFHR funds long-term study of HPV vaccine dosing

Image: A new long-term evaluation study funded by MSFHR aims to improve the use of the human papillomavirus (HPV) vaccine Gardasil™.

A new long-term evaluation study funded by MSFHR aims to improve the use of the human papillomavirus (HPV) vaccine Gardasil™.

The Quadrivalent HPV Vaccine Evaluation Study (QUEST) will evaluate whether an alternative-dose regimen of Gardasil™ is as effective as the standard three-dose treatment at preventing HPV infection and associated cervical cancers. The benefits of an alternative dose regimen could include significant cost savings and acceptability for future immunization programs.

QUEST will follow two cohorts of girls aged 9 to 12 who have received either an alternative dose with two doses to date or the standard three dose regimen of Gardasil™ and compare the vaccine’s effectiveness in both groups up to age 19. More than 8,500 study participants recruited from BC, Alberta, Quebec, and Atlantic Canada will be followed over a 10-year period. The goal of the evaluation study is to determine how long Gardasil™ remains effective in conferring protection and if, or when, booster doses are required to maintain immunity.

The study, which will be implemented by the Vaccine Evaluation Centre at BC Children’s Hospital, is led by Provincial Health Services Authority principal investigators Dr. Gina Ogilvie, Dr. Simon Dobson, and Dr. Mel Krajden. Funding for the project is provided by MSFHR with the support of the governments of several provinces and territories.